P-007 Comparison of methods for measuring total cell-free DNA and KRAS mutations in plasma from metastatic colorectal cancer patients

Podobne zapisy

• Total cell-free DNA, carcinoembryonic antigen, and C-reactive protein for assessment of prognosis in patients with metastatic colorectal cancer
  od: Karen-Lise Garm Spindler, i wsp.
  Wydane: (2018-11-01)
• PD-001 Total cell-free DNA level in plasma as strong prognostic marker in metastatic colorectal cancer
  od: Spindler, K.-L., i wsp.
  Wydane: (2016)
• KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer
  od: Spindler, K G, i wsp.
  Wydane: (2013)
• Measuring KRAS Mutations in Circulating Tumor DNA by Droplet Digital PCR and Next-Generation Sequencing
  od: Demuth, Christina, i wsp.
  Wydane: (2018)
• Response to comment on ‘KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer'
  od: Spindler, K-L G, i wsp.
  Wydane: (2014)